The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease, including the ongoing interventional Phase 1/2 ASTRA study and ...
SpliceBio is pleased to announce the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a g...
SpliceBio, compañía biotecnológica de terapia génica con sede en Barcelona basada en tecnología desarrollada en la Universidad de Princeton, ha recibido el galardón a la “Ronda de Inversión S...
SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...